Rapamycin-loaded solid lipid nanoparticles: Morphology and impact of the drug loading on the phase transition between lipid polymorphs

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 502, Issue , 2016, Pages 54-65

  Mazuryk, Jarosław ^a   Deptuła, Tobiasz ^a   Polchi, Alice ^b   Gapiński, Jacek ^a   Giovagnoli, Stefano ^b   Magini, Alessandro ^b   Emiliani, Carla ^b   Kohlbrecher, Joachim ^c   Patkowski, Adam ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

^b UNIVERSITY OF PERUGIA   (Italy)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Compritol; Drug delivery system; Phase transition; Polysorbate 80; Rapamycin; Solid lipid nanoparticles

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASE CONTROL; EMULSIFICATION; LIPID BILAYERS; LIQUID CRYSTALS; MORPHOLOGY; NANOPARTICLES; NEURODEGENERATIVE DISEASES; TARGETED DRUG DELIVERY;

COMPRITOL; DRUG DELIVERY SYSTEM; POLYSORBATE 80; RAPAMYCIN; SOLID LIPID NANOPARTICLE (SLN);

PHASE TRANSITIONS;

GLYCEROL BEHENATE; LIPID; POLYSORBATE 80; RAPAMYCIN; SOLID LIPID NANOPARTICLE; SURFACTANT;

ARTICLE; ATOMIC FORCE MICROSCOPY; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG RELEASE; HYDRODYNAMICS; INFRARED SPECTROSCOPY; LIGHT SCATTERING; LIPID BILAYER; NANOPHARMACEUTICS; NEUTRON SCATTERING; PARTICLE SIZE; PHASE TRANSITION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TEMPERATURE; THERMODYNAMICS; THICKNESS; ZETA POTENTIAL;

EID: 84966709062     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2016.05.017     Document Type: Article

References (75)

1. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
2. Blasi P., Giovagnoli S., Schoubben A., Ricci M., Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 2007, 59:454-477.
3. Abdelbary G., Fahmy R.H. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech 2009, 10:211-219.
4. Yuan H., Miao J., Du Y.Z., You J., Hu F.Q., Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 2008, 348:137-145.
5. Gokce E.H., Korkmaz E., Dellera E., Sandri G., Bonferoni M.C., Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int. J. Nanomed. 2012, 7:1841-1850.
6. Alex A., Paul W., Chacko A.J., Sharma C.P. Enhanced delivery of lopinavir to the CNS using Compritol-based solid lipid nanoparticles. Ther. Deliv. 2011, 2:25-35.
7. Kushwaha A.K., Vuddanda P.R., Karunanidhi P., Singh S.K., Singh S. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. BioMed Res. Int. 2013, 2013:584549.
8. Gupta M., Tiwari S., Vyas S.P. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm. Dev. Technol. 2013, 18:550-559.
9. Huang Z.R., Hua S.C., Yang Y.L., Fang J.Y. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol. Sin. 2008, 29:1094-1102.
10. Hippalgaonkar K., Adelli G.R., Hippalgaonkar K., Repka M.A., Majumdar S. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J. Ocul. Pharmacol. Ther. 2013, 29:216-228.
11. Aji Alex M.R., Chacko A.J., Jose S., Souto E.B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 2011, 42:11-18.
12. Brubach J.B., Jannin V., Mahler B., Bourgaux C., Lessieur P., Roy P., Ollivon M. Structural and thermal characterization of glyceryl behenate by X-ray diffraction coupled to differential calorimetry and infrared spectroscopy. Int. J. Pharm. 2007, 336:248-256.
13. Pivette P., Faivre V., Brubach J.B., Daste G., Ollivon M., Lesieur S. Polymorphism of glyceryl behenates: from the individual compounds to the pharmaceutical excipient. Chem. Phys. Lipids 2014, 183:191-203.
14. Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 1975, 28:721-726.
15. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10:868-880.
16. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
17. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285:13107-13120.
18. Luderer F., Lobler M., Rohm H.W., Gocke C., Kunna K., Kock K., Kroemer H.K., Weitschies W., Schmitz K.P., Sternberg K. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J. Biomater. Appl. 2011, 25:851-875.
19. Woo H.N., Chung H.K., Ju E.J., Jung J., Kang H.W., Lee S.W., Seo M.H., Lee J.S., Lee J.S., Park H.J., Song S.Y., Jeong S.Y., Choi E.K. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int. J. Nanomed. 2012, 7:2197-2208.
20. Lorne E., Zhao X., Zmijewski J.W., Liu G., Park Y.J., Tsuruta Y., Abraham E. Participation of mammalian target of rapamycin complex 1 in toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury. Am. J. Respir. Cell Mol. Biol. 2009, 41:237-245.
21. Shah M., Edman M.C., Janga S.R., Shi P., Dhandhukia J., Liu S., Louie S.G., Rodgers K., Mackay J.A., Hamm-Alvarez S.F. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjogren's syndrome. J. Controlled Release 2013, 171:269-279.
22. Simamora P., Alvarez J.M., Yalkowsky S.H. Solubilization of rapamycin. Int. J. Pharm. 2001, 213:25-29.
23. Hallensleben K., Raida M., Habermehl G. Identification of a new metabolite of macrolide immunosuppressant like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 2000, 11:516-525.
24. Emoto C., Fukuda T., Cox S., Christians U., Vinks A.A. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. Pharmacomet. Syst. Pharmacol. 2013, 2:e59.
25. Lemos P.A., Farooq V., Takimura C.K., Gutierrez P.S., Virmani R., Kolodgie F., Christians U., Kharlamov A., Doshi M., Sojitra P., van Beusekom H.M., Serruys P.W. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention 2013, 9:148-156.
26. Chen Y.C., Lo C.L., Lin Y.F., Hsiue G.H. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials 2013, 34:1115-1127.
27. Tai W., Chen Z., Barve A., Peng Z., Cheng K. A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharm. Res. 2014, 31:706-719.
28. Rouf M.A., Vural I., Renoir J.M., Hincal A.A. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J. Liposome Res. 2009, 19:322-331.
29. Schmiele M., Knittel C., Unruh T., Busch S., Morhenn H., Boesecke P., Funari S.S., Schweins R., Lindner P., Westermann M., Steiniger F. Analysis of the structure of nanocomposites of triglyceride platelets and DNA. Phys. Chem. Chem. Phys. 2015, 17:17939-17956.
30. Bunjes H., Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev. 2007, 59:379-402.
31. Muller R.H., Ruhl D., Runge S., Schulze-Forster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
32. Souto E.B., Muller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handbook of Experimental Pharmacology 2010, 4:115-141. Springer. http://link.springer.com/chapter/10.1007%2F978-3-642-00477-3_4.
33. Radomska-Soukharev A., Muller R.H. Chemical stability of lipid excipients in SLN-production of test formulations, characterisation and short-term stability. Die Pharmazie 2006, 61:425-430.
34. Kovacevic A., Savic S., Vuleta G., Muller R.H., Keck C.M. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int. J. Pharm. 2011, 406:163-172.
35. Blasi P., Giovagnoli S., Schoubben A., Puglia C., Bonina F., Rossi C., Ricci M. Lipid nanoparticles for brain targeting I. Formulation optimization. Int. J. Pharm. 2011, 419:287-295.
36. Blasi P., Schoubben A., Traina G., Manfroni G., Barberini L., Alberti P.F., Cirotto C., Ricci M. Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int. J. Pharm. 2013, 454:316-323.
37. Trepanier D.J., Gallant H., Legatt D.F., Yatscoff R.W. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin. Biochem. 1998, 31:345-351.
38. Uner M., Wissing S.A., Yener G., Muller R.H. Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Die Pharmazie 2004, 59:331-332.
39. Ricciutelli M., Di Martino P., Barboni L., Martelli S. Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC. J. Pharm. Biomed. Anal. 2006, 41:1070-1074.
40. Kamberi M., Tran T.N. UV-visible spectroscopy as an alternative to liquid chromatography for determination of everolimus in surfactant-containing dissolution media: a useful approach based on solid-phase extraction. J. Pharm. Biomed. Anal. 2012, 70:94-100.
41. Beattie J.R., Bell S.E., Moss B.W. A critical evaluation of Raman spectroscopy for the analysis of lipids: fatty acid methyl esters. Lipids 2004, 39:407-419.
42. Noack A., Hause G., Mader K. Physicochemical characterization of curcuminoid-loaded solid lipid nanoparticles. Int. J. Pharm. 2012, 423:440-451.
43. Belu A., Mahoney C., Wormuth K. Chemical imaging of drug eluting coatings: combining surface analysis and confocal Raman microscopy. J. Controlled Release 2008, 126:111-121.
44. Kuo Y.C., Chen H.H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 2009, 365:206-213.
45. Passerini N., Qi S., Albertini B., Grassi M., Rodriguez L., Craig D.Q. Solid lipid microparticles produced by spray congealing: influence of the atomizer on microparticle characteristics and mathematical modeling of the drug release. J. Pharm. Sci. 2010, 99:916-931.
46. Das S., Ng W.K., Kanaujia P., Kim S., Tan R.B. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf. B 2011, 88:483-489.
47. Urban-Morlan Z., Ganem-Rondero A., Melgoza-Contreras L.M., Escobar-Chavez J.J., Nava-Arzaluz M.G., Quintanar-Guerrero D. Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method. Int. J. Nanomed. 2010, 5:611-620.
48. Montasser I., Shahgaldian P., Perret F., Coleman A.W. Solid lipid nanoparticle-based calix[n]arenes and calix-resorcinarenes as building blocks: synthesis, formulation and characterization. Int. J. Mol. Sci. 2013, 14:21899-21942.
49. You J., Wan F., de Cui F., Sun Y., Du Y.Z., Hu F.Q. Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int. J. Pharm. 2007, 343:270-276.
50. zur Muhlen A., zur Muhlen E., Niehus H., Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm. Res. 1996, 13:1411-1416.
51. Anantachaisilp S., Smith S.M., Treetong A., Pratontep S., Puttipipatkhachorn S., Ruktanonchai U.R. Chemical and structural investigation of lipid nanoparticles: drug-lipid interaction and molecular distribution. Nanotechnology 2010, 21:125102.
52. Negi J.S., Chattopadhyay P., Sharma A.K., Ram V. Development and evaluation of glyceryl behenate based solid lipid nanoparticles (SLNs) using hot self-nanoemulsification (SNE) technique. Arch. Pharmacal Res. 2014, 37:361-370.
53. Shahgaldian P., Quattrocchi L., Gualbert J., Coleman A.W., Goreloff P. AFM imaging of calixarene based solid lipid nanoparticles in gel matrices. Eur. J. Pharm. Biopharm. 2003, 55:107-113.
54. Vitorino C., Carvalho F.A., Almeida A.J., Sousa J.J., Pais A.A. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf. B 2011, 84:117-130.
55. Kumar S., Randhawa J.K. Preparation and characterization of Paliperidone loaded solid lipid nanoparticles. Colloids Surf. B 2013, 102:562-568.
56. Seetapan N., Bejrapha P., Srinuanchai W., Ruktanonchai U.R. Rheological and morphological characterizations on physical stability of gamma-oryzanol-loaded solid lipid nanoparticles (SLNs). Micron 2010, 41:51-58.
57. Illing A., Unruh T. Investigation on the flow behavior of dispersions of solid triglyceride nanoparticles. Int. J. Pharm. 2004, 284:123-131.
58. Jores K., Mehnert W., Mader K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res. 2003, 20:1274-1283.
59. Gao K., Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 2006, 310:213-219.
60. Garcia de la Torre J.G., Bloomfield V.A. Hydrodynamic properties of complex, rigid, biological macromolecules: theory and applications. Q. Rev. Biophys. 1981, 14:81-139.
61. Venable R.M., Pastor R.W. Frictional models for stochastic simulations of proteins. Biopolymers 1988, 27:1001-1014.
62. Banachowicz E., Gapinski J., Patkowski A. Solution structure of biopolymers: a new method of constructing a bead model. Biophys. J. 2000, 78:70-78.
63. Harding S.E., Rowe A.J. Modeling biological macromolecules in solution. II. The general tri-axial ellipsoid. Biopolymers 1983, 22:1813-1829.
64. Schmiele M., Schindler T., Westermann M., Steiniger F., Radulescu A., Kriele A., Gilles R., Unruh T. Mesoscopic structures of triglyceride nanosuspensions studied by small-angle X-ray and neutron scattering and computer simulations. J. Phys. Chem. B 2014, 118:8808-8818.
65. Martins S.M., Sarmento B., Nunes C., Lucio M., Reis S., Ferreira D.C. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur. J. Pharm. Biopharm. 2013, 85:488-502.
66. Swindells D.C.N., White P.S., Findlay J.A. X-ray crystal-structure of Rapamycin, C51h79no13. Can. J. Chem. 1978, 56:2491-2492.
67. Lewis R.N., McElhaney R.N. Membrane lipid phase transitions and phase organization studied by Fourier transform infrared spectroscopy. Biochim. Biophys. Acta 2013, 1828:2347-2358.
68. Pietralik Z., Krzyszton R., Kida W., Andrzejewska W., Kozak M. Structure and conformational dynamics of DMPC/dicationic surfactant and DMPC/dicationic Surfactant/DNA systems. Int. J. Mol. Sci. 2013, 14:7642-7659.
69. Snyder R.G., Maroncelli M., Qi S.P., Strauss H.L. Phase transitions and nonplanar conformers in crystalline n-alkanes. Science 1981, 214:188-190.
70. Casal H.L., McElhaney R.N. Quantitative determination of hydrocarbon chain conformational order in bilayers of saturated phosphatidylcholines of various chain lengths by Fourier transform infrared spectroscopy. Biochemistry 1990, 29:5423-5427.
71. 2H NMR spectroscopic studies of hydrocarbon chain conformation and orientational order in the liquid-crystalline state. Biophys. J. 1994, 67:197-207.
72. Acevedo-Morantes C.Y., Acevedo-Morantes M.T., Suleiman-Rosado D., Ramirez-Vick J.E. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Drug Deliv. 2013, 20:338-348.
73. Priyanka K., Sathali A.A. Preparation and evaluation of montelukast sodium loaded solid lipid nanoparticles. J. Young Pharm. 2012, 4:129-137.
74. Rahman Z., Zidan A.S., Khan M.A. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2010, 76:127-137.
75. Yassin A.E., Anwer M.K., Mowafy H.A., El-Bagory I.M., Bayomi M.A., Alsarra I.A. Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int. J. Med. Sci. 2010, 7:398-408.